Utility of Blood-Based Markers for Predicting Amyloid-Related Imaging Abnormalities and Their Course in Mild Cognitive Impairment and Alzheimer’s Disease Subjects Undergoing Routine Clinical Treatment with Amyloid-Directed Antibodies


The National Institutes of Health has emphasized that understanding and preventing ARIA is a very high priority for research. To our knowledge, this is the first study to evaluate the utility of a broad range of blood-based biomarkers, including markers of angiogenesis, neuronal injury, vascular injury and inflammation, for predicting ARIA and its consequences in mild cognitive impairment and Alzheimer’s disease patients undergoing routine treatment with amyloid antibodies.

Funding to Date



Biomarkers/Diagnostics/Studies of Risk & Resilience, Foundational


P. Murali Doraiswamy, M.B.B.S.

Related Content: